Avalyn Pharma appointed Robert Meyer, M.D. as an independent Class II director and made him eligible for a $40,000 annual retainer. Meyer also received an option to buy 31,182 common shares, while his regulatory and life-sciences experience adds specialized expertise to the board’s oversight of drug-development matters.
Key Highlights
- Robert Meyer received an option to purchase 31,182 shares of Avalyn Pharma common stock.
- Meyer previously held senior regulatory roles at the FDA and Merck Research Laboratories.
- The compensation policy provides eligible continuing directors with annual Options for 15,591 common shares.
Avalyn Pharma Inc. (NASDAQ: AVLN) appointed Robert Meyer, M.D. As an independent Class II director, making him eligible for a $40,000 annual retainer. The board selected Meyer following a recommendation from its Nominating and Corporate Governance Committee.
31,182-Share Initial Option Grant
Meyer received an option to purchase 31,182 shares of Avalyn Pharma common stock, which has a Par Value of $0.001 per share. The grant vests in equal annual installments under its stated vesting schedule, and its exercise price is set at the common stock’s fair Market Value on the grant date. Meyer will also be eligible for an annual option grant covering 15,591 common shares while he remains a director. His first annual grant will be prorated monthly based on his service, while grants to continuing non-employee directors vest under the compensation policy’s annual meeting terms.
Regulatory and Board Experience
Avalyn Pharma cited Meyer’s experience advising on drug-approval matters, serving on public life-sciences company boards and practicing medicine as qualifications for the appointment. He also signed an indemnification agreement consistent with those used for the company’s existing non-employee directors.
FAQs
Q: How many Avalyn Pharma shares can Robert Meyer purchase under his initial stock option?
A: Robert Meyer’s initial grant covers an option to purchase 31,182 Avalyn Pharma common shares. The award carries an exercise price equal to fair market value on its grant date.
Q: What annual compensation is Robert Meyer eligible to receive as an Avalyn Pharma director?
A: Meyer is eligible for a $40,000 annual retainer under Avalyn Pharma’s Non-Employee Director Compensation Policy. He may also receive annual stock-option grants while serving on the board.
Q: What additional stock option can Robert Meyer receive while serving as a director?
A: Meyer is eligible for an annual option covering 15,591 Avalyn Pharma common shares. His first annual grant will be prorated monthly according to his time served as a director.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.